Brown Miller Wealth Management LLC Purchases 317 Shares of Amgen Inc. $AMGN

Brown Miller Wealth Management LLC raised its position in Amgen Inc. (NASDAQ:AMGN) by 4.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,844 shares of the medical research company’s stock after purchasing an additional 317 shares during the quarter. Brown Miller Wealth Management LLC’s holdings in Amgen were worth $2,190,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. OLD National Bancorp IN grew its holdings in shares of Amgen by 296.2% during the second quarter. OLD National Bancorp IN now owns 18,004 shares of the medical research company’s stock worth $5,027,000 after purchasing an additional 13,460 shares during the last quarter. Carolina Wealth Advisors LLC boosted its position in Amgen by 1,100.0% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 264 shares of the medical research company’s stock worth $74,000 after buying an additional 242 shares during the period. Capital City Trust Co. FL grew its holdings in Amgen by 2.3% during the 2nd quarter. Capital City Trust Co. FL now owns 6,825 shares of the medical research company’s stock worth $1,906,000 after acquiring an additional 155 shares during the last quarter. Tandem Investment Partners LLC increased its position in Amgen by 17.2% in the 2nd quarter. Tandem Investment Partners LLC now owns 2,047 shares of the medical research company’s stock valued at $572,000 after acquiring an additional 300 shares during the period. Finally, O Keefe Stevens Advisory Inc. increased its position in Amgen by 2.0% in the 2nd quarter. O Keefe Stevens Advisory Inc. now owns 49,980 shares of the medical research company’s stock valued at $13,955,000 after acquiring an additional 981 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Up 0.2%

Shares of NASDAQ:AMGN opened at $297.89 on Friday. The business’s 50 day moving average is $287.34 and its 200 day moving average is $288.17. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $335.88. The stock has a market cap of $160.37 billion, a price-to-earnings ratio of 24.36, a PEG ratio of 2.59 and a beta of 0.49. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business had revenue of $9.18 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same period last year, the business earned $4.97 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were paid a $2.38 dividend. The ex-dividend date was Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.2%. Amgen’s dividend payout ratio (DPR) is 77.84%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.76% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on AMGN. UBS Group cut their price target on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a report on Wednesday, August 6th. Bank of America lifted their target price on Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a report on Friday, September 26th. Piper Sandler upped their price target on Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research report on Monday, August 25th. William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, June 24th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Amgen in a report on Saturday, September 27th. Seven analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $309.70.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.